US 2026/0284226 A1 · METHODS AND COMPOSITIONS FOR CANCER TREATMENT USING RECOMBINANT POLYPEPTIDES

Abstract

Disclosed hereopin are methods for the treatment of cancer in a human subject comprising administration of a recombinant polypeptide comprising a cancer-specific CD8+ T cell epitope. Peptides recognized by major histocompatibility complex (MHC) molecules can activate a T cell immune response to target cancer cells in a subject. The present disclosure furthermore provides cancer-specific CD8+ T cell epitopes restricted to MHC molecules expressed by specific HLA-Alleles in a subject. The present disclosure furthermore provides a composition encoding the recombinant polypeptide which is capable of eliciting an inflating memory CD8+ T cell response.

Claims21

Dependent claims

-121. (canceled)

A method of treating a cancer in a human subject in need thereof, comprising administering to the human subject a pharmaceutical composition comprising:

(i) a polypeptide that is from 9 to 11 amino acids in length, wherein the polypeptide comprises a single cancer-specific CD8+ T cell epitope;
(ii) a recombinant polynucleotide comprising a sequence encoding a polypeptide that is from 9 to 11 amino acids in length, wherein the polypeptide comprises a single cancer-specific CD8+ T cell epitope;
(iii) a vector comprising (ii);
(iv) antigen presenting cells (APCs) comprising (i), (ii), or (iii);
or
(v) T cells stimulated with APCs comprising (i), (ii), or (iii);
wherein:
(a) the human subject expresses an MHC encoded by an HLA-B*35:03 allele or an HLA-B*07:02 allele, and the single cancer-specific CD8+ T cell epitope has the amino acid sequence SPSSASLAL or KPRPDVTNEL;
(b) the human subject expresses an MHC encoded by an HLA-A*02:01 allele and the single cancer-specific CD8+ T cell epitope has the amino acid sequence GVYDGREHTV or KL VELEHTL;
(c) the human subject expresses an MHC encoded by an HLA-B*40:01 allele, an HLA-B*40:02 or an HLA-B*44:02 allele, and the single cancer-specific CD8+ T cell epitope has the amino acid sequence KEFAFLEHSL or HELGFKVVL;
(d) the human subject expresses an MHC encoded by an HLA-B*18:01 allele and the single cancer-specific CD8+ T cell epitope has the amino acid sequence HELGFKVVL;
and/or
(e) the human subject expresses an MHC encoded by an HLA-A*03:01 allele and the single cancer-specific CD8+ T cell epitope has the amino acid sequence RVSLPKLGYK.

10 more elements

Dependencies are inferred from the claim text.

Facts

Application

19/350,488Filed 6 Oct 2025

Priority

7 Apr 2023

Published

24 Sep 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

A61K 48/005
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy:…
A61K 35/17
Blood; Artificial blood: lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 38/08
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: peptides having 5 to 11 amino acids
A61K 39/001111
Receptors, cell surface antigens or cell surface determinants: immunoglobulin superfamily

Methods and compositions for cancer treatment using recombinant polypeptides

Life of this patent

Methods and compositions for cancer treatment using recombinant polypeptides

Life of this patent

Abstract

Claims21